Sleep fragmentation, which is defined by low sleep efficiency, was linked with higher odds of migraine onset on day 1, according to study findings published this week.
Sleep fragmentation, which is defined by low sleep efficiency, was linked with higher odds of migraine onset on day 1, according to study findings published this week in the journal Neurology.
In nearly half of all patients with migraine, sleep disturbance is reported as a trigger for symptom recurrence. However, the attributable cause of this association has not been delineated through prior studies. Lead study author Suzanne Bertisch, MD, MPH, physician and clinical investigator in the Division of Sleep and Circadian Disorders at the Brigham and Women’s Hospital, noted that many patients with migraine who also suffer from insomnia are referred to her in the sleep clinic, but the lack of data on the relationship makes it difficult to choose which treatments would work best.
“Anyone treating these patients wants to be able to counsel them on what to do to decrease their risk of a migraine, but the literature is unclear on what kind of sleep interventions may be helpful," said Bertisch.
Researchers sought to evaluate the temporal relationship between sleep and migraine onset through focusing on hypotheses such as insufficient duration, high fragmentation, and poor sleep quality. Assessments were conducted in the largest prospective study to date to examine objective measures of sleep:
Results were derived from 4406 days of data, with 870 headaches reported among the study cohort. In the analysis, sleep duration (≤6.5) and poor sleep quality were not found to be associated with onset migraine on day 0 or day 1.
Conversely, sleep fragmentation exhibited a definite relationship with migraine onset as diary-reported low efficiency was linked with 39% higher odds of headache on day 1 (odds ratio [OR] = 1.39; 95% CI, 1.06—1.81) and actigraphic-assessed high fragmentation was associated with lower odds of migraine on day 0 (wake after sleep onset >53 minutes; OR = 0.64, 95% CI, 0.48-0.86; efficiency ≤ 88%, OR = 0.74, 95% CI, 0.56–0.99).
"Sleep is multi-dimensional, and when we look at certain aspects such as sleep, we found that low sleep efficiency, which is the amount of time you're awake in bed when you're trying to sleep, was associated with migraines not on the day immediately following, but on the day after that," said Bertisch. Although short sleep duration and low sleep quality were not found to be temporally associated with migraine, the study authors noted that the link found between sleep fragmentation and risk of migraine warrants further research to understand the clinical and neurobiologic implications.
Reference
Bertisch SM, Li W, Buettner C, et al. Nightly sleep duration, fragmentation, and quality and daily risk of migraine. [published online December 16, 2019]. Neurology. doi: 10.1212/WNL.0000000000008740.
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen